News

LEO has plans for Spevigo beyond generalised pustular psoriasis as it looks to boost its dermatological pipeline.
Vertex Pharmaceuticals has announced a reimbursement agreement with NHS England for its cystic fibrosis (CF) medicine, Alyftrek.
Ultragenyx Pharmaceuticals has announced the extension of approval by Health Canada for Evkeeza (evinacumab) for HoFH.
WHO’s director general described the policy guidelines for Gilead’s twice-yearly drug as the “next best thing” in the absence of a vaccine.
Illimis has completed a Series B funding round, securing $42m for the development of its GAIA-based Alzheimer's disease therapeutics.
In a recent webinar, industry experts explain how real-world data and patient-centric support can shape regulatory success ...
Ultragenyx Pharmaceutical has received a complete response letter (CRL) from the FDA concerning its BLA for UX111 (ABO-102).
The label expansion sought by GSK is a bid to compete with Pfizer and Moderna in the younger age groups of the RSV vaccine market. Pfizer’s Abrysvo and Moderna’s mRESVIA are both approved to prevent ...
The US dominates overall sales, yet GlobalData predicts that China is shaping up to be a formidable presence in the cell therapy space.
With clinical trials under pressure, industry leaders say it’s time for reform, digital transformation, and more patient-centric models.
The DoH and Children’s National Hospital in the US have signed a MoU to advance paediatric cell and gene therapy.
IGI Therapeutics has signed an exclusive licensing agreement with AbbVie, for ISB 2001 to treat cancer and autoimmune diseases.